Surgery, Gastroenterology and Oncology
Official journal of the International Association of Surgeons, Gastroenterologists and Oncologists
|
|
Clinical and Endoscopic Profile of Periampullary Tumour in a Tertiary Care Hospital
Background and aims: Periampullary tumour is a clinical condition often encountered by gastroenterologist and surgeon. There is limited data regarding clinical profile and endoscopic management of patients with periampullary tumour.
Methods: We retrospectively analyzed the ERCP (Endoscopic retrograde cholangio pancreatography) records of periampullary tumour patients who were referred to Department of Gastroenterology for ERCP over a period of three years from January 2015 to January 2018. Demographic profile, clinical findings and ERCP management were taken into consideration. Statistics used were mean and standard deviation for continuous variables, frequencies and percentages were calculated for categorical Variables were determined.
Results: We retrospectively analyzed 86 patients who had undergone ERCP for Periampullary tumours from January 2015 to January 2018. Data interpretation revealed, that majority of the cases were between 41 to 50 years (23.6 %). There was a male preponderance (66.3%). Maximum number of cases were of ampullary growth (46.5 %), followed by lower CBD stricture (32.6 %). The predominant presenting symptom was jaundice (77.9%), followed by abdominal pain (54.6 %). 12 patients (14%) had cholangitis at presentation. Mean bilirubin in the current study ranged from 11.76 to 23.72. CBD cannulation was achieved in 98.8% cases (Selective cannulation 65.1%, precut sphincterotomy 33.7%). Biliary drainage was done using plastic biliary stent (PC) in 84.7% and SEMS (self-expandable metallic stent) in 15.2% cases. Ampullary growth biopsy and biliary brush cytology revealed malignancy in 55% and 35.7% cases respectively. At 3 months, 4 patients with PC stent developed block.
Conclusion: In our study, ampullary growth was the most common type of Periampullary tumour. Cholangitis was present in 14% cases at presentation. ERCP had good success for biliary drainage.Ampullary growth biopsy and biliary brush cytology has sensitivity rate of 50% and 35.7% respectively. Rate of PC stent block was low (< 5%).
Full Text Sources:
Abstract:
Views: 3180
Methods: We retrospectively analyzed the ERCP (Endoscopic retrograde cholangio pancreatography) records of periampullary tumour patients who were referred to Department of Gastroenterology for ERCP over a period of three years from January 2015 to January 2018. Demographic profile, clinical findings and ERCP management were taken into consideration. Statistics used were mean and standard deviation for continuous variables, frequencies and percentages were calculated for categorical Variables were determined.
Results: We retrospectively analyzed 86 patients who had undergone ERCP for Periampullary tumours from January 2015 to January 2018. Data interpretation revealed, that majority of the cases were between 41 to 50 years (23.6 %). There was a male preponderance (66.3%). Maximum number of cases were of ampullary growth (46.5 %), followed by lower CBD stricture (32.6 %). The predominant presenting symptom was jaundice (77.9%), followed by abdominal pain (54.6 %). 12 patients (14%) had cholangitis at presentation. Mean bilirubin in the current study ranged from 11.76 to 23.72. CBD cannulation was achieved in 98.8% cases (Selective cannulation 65.1%, precut sphincterotomy 33.7%). Biliary drainage was done using plastic biliary stent (PC) in 84.7% and SEMS (self-expandable metallic stent) in 15.2% cases. Ampullary growth biopsy and biliary brush cytology revealed malignancy in 55% and 35.7% cases respectively. At 3 months, 4 patients with PC stent developed block.
Conclusion: In our study, ampullary growth was the most common type of Periampullary tumour. Cholangitis was present in 14% cases at presentation. ERCP had good success for biliary drainage.Ampullary growth biopsy and biliary brush cytology has sensitivity rate of 50% and 35.7% respectively. Rate of PC stent block was low (< 5%).
Full Text Sources:
Abstract:
Views: 3180
Watch Video Articles
For Authors
Journal Subscriptions
Current Issue
Mar 2026
Supplements
Instructions for authors
Online submission
Contact
ISSN: 2559 - 723X (print)
e-ISSN: 2601 - 1700 (online)
ISSN-L: 2559 - 723X
Journal Abbreviation: Surg. Gastroenterol. Oncol.
Surgery, Gastroenterology and Oncology (SGO) is indexed in:
e-ISSN: 2601 - 1700 (online)
ISSN-L: 2559 - 723X
Journal Abbreviation: Surg. Gastroenterol. Oncol.
Surgery, Gastroenterology and Oncology (SGO) is indexed in:
- SCOPUS
- EBSCO
- DOI/Crossref
- Google Scholar
- SCImago
- Harvard Library
- Open Academic Journals Index (OAJI)
Open Access Statement
Surgery, Gastroenterology and Oncology (SGO) is an open-access, peer-reviewed online journal published by Celsius Publishing House. The journal allows readers to read, download, copy, distribute, print, search, or link to the full text of its articles.
Surgery, Gastroenterology and Oncology (SGO) is an open-access, peer-reviewed online journal published by Celsius Publishing House. The journal allows readers to read, download, copy, distribute, print, search, or link to the full text of its articles.
Journal Metrics
Time to first editorial decision: 25 days
Rejection rate: 61%
CiteScore: 0.2
Time to first editorial decision: 25 days
Rejection rate: 61%
CiteScore: 0.2
IASGO Society News
Meetings and Courses in 2025
Meetings and Courses in 2024
Meetings and Courses in 2023
Meetings and Courses in 2022
Meetings and Courses in 2021
Meetings and Courses in 2020
Meetings and Courses in 2019
Verona expert meeting 2019
Surgery, Gastroenterology and Oncology applies the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits readers to copy and redistribute the material in any medium or format, remix, adapt, build upon the published works non-commercially, and license the derivative works on different terms, provided the original material is properly cited and the use is non-commercial. Please see: https://creativecommons.org/licenses/by-nc/4.0/
Publisher’s Note:
The opinions, statements, and data contained in article are solely those of the authors and not of Surgery, Gastroenterology and Oncology journal or the editors. Publisher and the editors disclaim responsibility for any damage resulting from any ideas, instructions, methods, or products referred to in the content.